Literature DB >> 26254397

Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotype to Gastric Cancer Risk in Taiwan.

Hong-Xue Ji1, Wen-Shin Chang1, Chia-Wen Tsai2, Ju-Yu Wang3, Nai-Kuei Huang4, An-Sheng Lee5, Ming-Yi Shen6, Wei-Yu Chen7, Yao-Chang Chiang8, Tzu-Ching Shih9, Chin-Mu Hsu10, Da-Tian Bau11.   

Abstract

AIM: It has been proposed that genetic variations of DNA repair genes confer susceptibility to cancer, and the DNA repair gene xeroderma pigmentosum group D (XPD), the caretaker of genome stability, is thought to play a major role in the nucleotide excision repair system. We investigated three genotypes of XPD, at promoter -114 (rs3810366), and codon 312 (rs1799793), 751 (rs13181), and their associated with gastric cancer susceptibility in a Taiwanese population.
MATERIALS AND METHODS: In the present study, 121 patients with gastric cancer and 363 gender- and age-matched healthy controls were recruited and genotyped for XPD by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) methodology, and the association of XPD genotype with gastric cancer risk was investigated.
RESULTS: We found a significant difference in the distribution of A allele-bearing XPD codon 312 genotypes [odds ratio (OR)=1.64, 95% confidence interval (CI)=1.20-2.25, p=0.0019], but not in XPD codon 751 or promoter -114 sites, between the gastric cancer and control groups. Those who had G/A or A/A at XPD codon 312 had a 1.83-fold (95% CI=1.14-2.95, p=0.0159) and 1.87-fold (95% CI=1.04-3.34, p=0.0378) increased risk of gastric cancer compared to those with G/G. The risk for G/A and A/A genotypes had synergistic effects with alcohol drinking (OR=11.27, 95% CI=3.72-34.17, p=0.0001), cigarette smoking (OR=23.20, 95% CI=6.24-86.23, p=0.0001) and Helicobacter pylori infection (OR=5.38, 95% CI=2.76-10.52, p=0.0001) on gastric cancer susceptibility.
CONCLUSION: Our findings suggest that the A allele of XPD codon 312 may contribute to gastric carcinogenesis and may be useful for early detection and prevention of gastric cancer. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Alcohol consumption; XPD; gastric cancer; genotype; polymorphism; smoking

Mesh:

Year:  2015        PMID: 26254397

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan.

Authors:  Mei-Due Yang; Kuo-Cheng Lin; Meng-Chun Lu; Long-Bin Jeng; Chieh-Lun Hsiao; Te-Cheng Yueh; Chun-Kai Fu; Hsin-Ting Li; Shiou-Ting Yen; Chia-Wen Lin; Cin-Wun Wu; Su-Yi Pang; Da-Tian Bau; Fuu-Jen Tsai
Journal:  Biomedicine (Taipei)       Date:  2017-06-14

2.  Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.

Authors:  Fei Chen; Sungshim L Park; Lynne R Wilkens; Peggy Wan; Steven N Hart; Chunling Hu; Siddhartha Yadav; Fergus J Couch; David V Conti; Adam J de Smith; Christopher A Haiman
Journal:  Cancer Res       Date:  2022-09-16       Impact factor: 13.312

3.  Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.

Authors:  Gloria Ravegnini; Margherita Nannini; Vittorio Simeon; Muriel Musti; Giulia Sammarini; Maristella Saponara; Lidia Gatto; Milena Urbini; Annalisa Astolfi; Guido Biasco; Maria A Pantaleo; Nicola Venturoli; Patrizia Hrelia; Sabrina Angelini
Journal:  Tumour Biol       Date:  2016-07-27

4.  Impact of polymorphisms in DNA repair genes XPD, hOGG1 and XRCC4 on colorectal cancer risk in a Chinese Han Population.

Authors:  Dexi Jin; Min Zhang; Hongjun Hua
Journal:  Biosci Rep       Date:  2019-01-15       Impact factor: 3.840

5.  Association between NER Pathway Gene Polymorphisms and Wilms Tumor Risk.

Authors:  Jinhong Zhu; Wen Fu; Wei Jia; Huimin Xia; Guo-Chang Liu; Jing He
Journal:  Mol Ther Nucleic Acids       Date:  2018-08-08       Impact factor: 8.886

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.